Ocuphire Pharma Inc (R3X1.MU)

Compare

1.0580

0.0000

(0.00%)

At close: January 31 at 8:00:44 AM GMT+1

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Agreement Reached on Primary Endpoint and Phase 3 Trial Design Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small-molecule drugs to treat other ophthalmologic disorders, today announced that it has reached agreement with the U.S. Food and Drug Adm

GlobeNewswire last month

IRD
Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024

6-month efficacy and safety data from ongoing Phase 1/2 trial of OPGx-LCA5 to be presentedFARMINGTON HILLS, Mich., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other ophthalmic disorders, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, December 11, 2024 at 4:00 PM ET. To register, click here. The ev

GlobeNewswire last month

IRD
Opus Genetics reinstated with a Buy at H.C. Wainwright

H.C. Wainwright reinstated coverage of Opus Genetics (IRD) with a Buy rating and $8 price target The firm believes inherited retinal disease development presents an efficient path to concise studies offering insight into gene therapy efficacy. The firm believes the company’s 2025 catalysts can give the its platform the appropriate foundation for continued innovation and development over the near-term. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial

TipRanks 2 months ago

IRD
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FARMINGTON HILLS, Mich., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other ophthalmological disorders (the “Company”), today announced that the independent members of its Board of Directors approved an equity award under the Company’s 2021 Inducement Plan, as amended, as a material inducement to Dr. Benja

GlobeNewswire 2 months ago

IRD
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics

The RD Fund (Retinal Degeneration Fund) – the venture arm of the Foundation Fighting Blindness – announces the all-stock acquisition of Opus Genetics, Inc. "Opus" (private) by Ocuphire Pharma, Inc., (Nasdaq: OCUP) a clinical-stage ophthalmic biopharmaceutical company. The companies have combined under the name of Opus Genetics to create a transformative biotech company committed to being a leader in the development of gene therapies for the treatment of inherited retinal diseases (IRDs). The com

PR Newswire 3 months ago

IRD

OCUP
Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics

Ocuphire Pharma ( (OCUP) ) just unveiled an update. Ocuphire Pharma has acquired Opus Genetics in an all-stock merger, forming a leading biotech company focused on gene therapies for inherited retinal diseases (IRDs). This strategic move will see the company renamed Opus Genetics, Inc. and trading under the ticker ‘IRD.’ With promising early data, the merger brings together a strong leadership team to advance groundbreaking therapies, while extending the cash runway into 2026. Investors can expe

TipRanks 3 months ago

OCUP
Ocuphire Pharma Announces Acquisition of Opus Genetics

Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Phase 1/2 6-month data demonstrate safety and visual improvement in early onset retinal degeneration Additional clinical data in LCA5 pediatric patients and BEST1 patients is expected in 2H 2025 LYNX-2 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% in patients with dim light disturbances remains on track for top-line data in Q

GlobeNewswire 3 months ago

OCUP
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology

Published data from two Phase 3 clinical trials demonstrated rapid reversal of pharmacologically-induced mydriasis with favorable safety profileFARMINGTON HILLS, Mich., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced the publication of full results from two pivotal

GlobeNewswire 4 months ago

OCUP
UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia

Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual acuity under low light conditions following keratorefractive surgery expected in first quarter of 2025 FARMINGTON HILLS, Mich., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients wit

GlobeNewswire 4 months ago

OCUP
Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia

Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual acuity under low light conditions following keratorefractive surgery expected in first quarter of 2025 FARMINGTON HILLS, Mich., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients wit

GlobeNewswire 4 months ago

OCUP
Ocuphire Pharma, Inc. (NASDAQ:OCUP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

One of the biggest stories of last week was how Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) shares plunged 29% in the week...

Simply Wall St. 5 months ago

OCUP
Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update

VEGA-3 Phase 3 Study of Phentolamine Ophthalmic Solution in Presbyopia is Recruiting Patients with Top-Line Data Expected in 2025 LYNX-2 Phase 3 Study of Phentolamine Ophthalmic Solution Continues Enrollment with Top-Line Data Expected in 2025 Preparatory Steps Towards Phase 2/3 with APX3330 in Diabetic Retinopathy are Ongoing Cash Position of $41.4 million Provides Runway Anticipated into mid-2025 FARMINGTON HILLS, Mich., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a

GlobeNewswire 5 months ago

OCUP
Ocuphire Pharma to Present at Two Investor Conferences in August

FARMINGTON HILLS, Mich., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that George Magrath, M.D., M.B.A., M.S., Chief Executive Officer, will present at the Canaccord Genuity 44th Annual Growth Conference, to take place in Boston, MA, August 14, 2024, and at the H

GlobeNewswire 5 months ago

OCUP
Here's Why We're Not At All Concerned With Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Simply Wall St. 5 months ago

OCUP
Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July

CEO to participate in ARVO SIG panel on oral medications for retinal diseases ZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42nd Annual Scientific Meeting FARMINGTON HILLS, Mich., July 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced it wil

GlobeNewswire 6 months ago

OCUP
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June

FARMINGTON HILLS, Mich., June 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that clinical updates on the Company’s lead candidate APX3330 for diabetic retinopathy (DR) will be featured in upcoming presentations at the Clinical Trials at the Summit meeting on June 8 in Park City, Utah, a

GlobeNewswire 7 months ago

OCUP
Ocuphire Pharma First Quarter 2024 Earnings: Misses Expectations

Ocuphire Pharma ( NASDAQ:OCUP ) First Quarter 2024 Results Key Financial Results Revenue: US$1.71m (down 2.2% from 1Q...

Simply Wall St. 8 months ago

OCUP
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update

FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update. “Ocuphire has made significant progress in 2024, with important developments for both APX3330 and RYZUMVI™,” said Georg

GlobeNewswire 8 months ago

OCUP
Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting

FARMINGTON HILLS, Mich., May 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that clinical data from its ZETA-1 trial evaluating APX3330 in diabetic retinopathy (DR) on a validated binocular person-level scale was presented yesterday at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meet

GlobeNewswire 8 months ago

OCUP
Ocuphire Pharma to Present at the Aegis Virtual Conference

FARMINGTON HILLS, Mich., May 03, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that George Magrath, M.D. M.B.A., M.S., Chief Executive Officer of Ocuphire, will present a company overview at the Aegis Virtual Conference being held May 7-9, 2024. Company management will also be participating in one-on-one meetings throughout t

GlobeNewswire 8 months ago

OCUP

Performance Overview

Return	R3X1.MU	S&P 500
YTD	-4.34%	+2.26%
1-Year	-58.75%	+22.65%
3-Year	-57.34%	+36.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ocuphire Pharma Inc (R3X1.MU)

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Opus Genetics to Host Virtual KOL Event on OPGx-LCA5 as a Treatment for LCA5-Associated Inherited Retinal Disease on December 11, 2024

Opus Genetics reinstated with a Buy at H.C. Wainwright

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics

Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics

Ocuphire Pharma Announces Acquisition of Opus Genetics

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology

UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia

Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia

Ocuphire Pharma, Inc. (NASDAQ:OCUP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update

Ocuphire Pharma to Present at Two Investor Conferences in August

Here's Why We're Not At All Concerned With Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation

Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July

Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June

Ocuphire Pharma First Quarter 2024 Earnings: Misses Expectations

Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update

Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting

Ocuphire Pharma to Present at the Aegis Virtual Conference

Performance Overview